CalciMedica Inc Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2007

Location

La Jolla CA US

Primary Industry

Pharmaceuticals

About

Founded in 2007 and based in California, US, CalciMedica Inc. develops pharmaceutical drugs using small-molecule procedures that provide treatment for autoimmune disorders, organ transplant rejection, and other immune diseases. In January 2024, CalciMedica Inc. raised USD 20.4 million in PIPE funding from Deerfield Management, Soleus Capital, Stonepine Capital Management, and Aisling Capital, including Sanderling Ventures and Bering Capital. As of 2024, the company is led by its CEO, Rachel Leheny. The company focuses on developing therapies to treat life-threatening inflammatory diseases, specifically targeting the pancreas, kidney, and lung. The firm's research is centered on CRAC (calcium release-activated calcium) channel inhibitors, which are a class of drugs designed to modulate immune responses and protect against tissue damage. CalciMedica’s lead product, Auxora™, is an intravenous formulation in development for acute pancreatitis with systemic inflammatory response syndrome (SIRS) and asparaginase-induced pancreatic toxicity (AIPT).

Current Investors

Sanderling Ventures, SR One, Mesa Verde Venture Partners

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Website

www.calcimedica.com/

Company Stage

Merged

Total Amount Raised

Subscriber access only

Deals

Deals Type
PIPE

Deal Status	Target (s)	Deal Date	Investor(s)	Seller(s)	Deal size (Mn)	Enterprise value (Mn)	Post-money valuation (Mn)	EBITDA multiple (x)	Revenue multiple (x)	Lead partner (s)
Completed	CalciMedica Inc	19 Jan 2024

Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.